Taewon Kim

Taewon Kim is a highly experienced professional in the pharmaceutical and healthcare industries, currently serving as Senior Director of Global Commercial Product Strategy for HBV/HDV at Gilead Sciences since 2020. In this role, Taewon leads the global HBV portfolio, including the promotion of Hepcludex, the sole treatment for chronic hepatitis delta. Prior experience includes serving as Franchise Lead at Takeda, where Taewon managed a portfolio exceeding $1 billion in sales, and held various marketing leadership roles at Baxter Healthcare, Eisai, and Bristol-Myers Squibb. Taewon's military background as an officer in the United States Air Force and advanced degrees, including an MBA in Marketing and Strategy from Georgetown University, complement a robust career trajectory marked by successful product launches and strategic market planning.